Labcorp Holdings Inc
LH251.810USD
-2.860-1.12%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
20.90BMarket Cap
24.56P/E TTM
More Details of Labcorp Holdings Inc Company
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
Labcorp Holdings Inc Info
Ticker SymbolLH
Company nameLabcorp Holdings Inc
IPO dateApr 24, 1991
CEOSchechter (Adam H)
Number of employees70000
Security typeOrdinary Share
Fiscal year-endApr 24
Address358 S Main St
CityBURLINGTON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code27215
Phone13362291127
Websitehttps://www.labcorp.com/
Ticker SymbolLH
IPO dateApr 24, 1991
CEOSchechter (Adam H)
Company Executives of Labcorp Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+757.00%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.73K
+263.00%
Ms. Megan D. Bailey
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
3.59K
+191.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-5745.00%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-2000.00%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+1972.00%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-4000.00%
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 12
Currency: USDUpdated: Wed, Mar 12
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Other
72.54%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
Other
72.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.39%
Investment Advisor/Hedge Fund
38.82%
Research Firm
2.40%
Pension Fund
1.76%
Hedge Fund
1.61%
Bank and Trust
1.56%
Sovereign Wealth Fund
1.25%
Individual Investor
0.36%
Family Office
0.26%
Other
1.59%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1803
80.86M
97.54%
-4.56M
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.78M
11.79%
-66.55K
-0.68%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.39M
5.3%
-10.58K
-0.24%
Sep 30, 2025
State Street Investment Management (US)
3.83M
4.62%
-31.13K
-0.81%
Sep 30, 2025
Victory Capital Management Inc.
2.64M
3.18%
+440.22K
+20.04%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.12M
2.56%
+9.78K
+0.46%
Sep 30, 2025
Wellington Management Company, LLP
2.11M
2.54%
+289.03K
+15.91%
Sep 30, 2025
Allspring Global Investments, LLC
2.00M
2.41%
-4.51K
-0.23%
Sep 30, 2025
Select Equity Group, L.P.
1.84M
2.22%
-295.76K
-13.87%
Sep 30, 2025
Diamond Hill Capital Management Inc.
1.64M
1.98%
-181.26K
-9.94%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.25M
1.5%
-41.66K
-3.23%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares U.S. Healthcare Providers ETF
3.32%
Knowledge Leaders Developed World ETF
2.73%
Thrivent Small-Mid Cap ESG ETF
2.26%
State Street SPDR S&P Health Care Services ETF
1.9%
Schwab Ariel Opportunities ETF
1.62%
Brandes US Value ETF
1.56%
Invesco S&P 500 Equal Weight Health Care ETF
1.52%
Madison Covered Call ETF
1.49%
Nuveen ESG Mid-Cap Value ETF
1.4%
Franklin Genomic Advancements ETF
1.25%
View more
iShares U.S. Healthcare Providers ETF
Proportion3.32%
Knowledge Leaders Developed World ETF
Proportion2.73%
Thrivent Small-Mid Cap ESG ETF
Proportion2.26%
State Street SPDR S&P Health Care Services ETF
Proportion1.9%
Schwab Ariel Opportunities ETF
Proportion1.62%
Brandes US Value ETF
Proportion1.56%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.52%
Madison Covered Call ETF
Proportion1.49%
Nuveen ESG Mid-Cap Value ETF
Proportion1.4%
Franklin Genomic Advancements ETF
Proportion1.25%
Dividend
A total of
692.30M
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 08, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 11, 2025 going ex on Nov 26, 2025
Nov 26, 2025
Dec 11, 2025
Nov 26, 2025
Jul 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 11, 2025 going ex on Aug 28, 2025
Aug 28, 2025
Sep 11, 2025
Aug 28, 2025
Apr 10, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 11, 2025 going ex on May 29, 2025
May 29, 2025
Jun 11, 2025
May 29, 2025
Jan 09, 2025
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Labcorp Holdings Inc?
The top five shareholders of Labcorp Holdings Inc are:
The Vanguard Group, Inc. holds 9.78M shares, accounting for 11.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.39M shares, accounting for 5.30% of the total shares.
State Street Investment Management (US) holds 3.83M shares, accounting for 4.62% of the total shares.
Victory Capital Management Inc. holds 2.64M shares, accounting for 3.18% of the total shares.
Geode Capital Management, L.L.C. holds 2.12M shares, accounting for 2.56% of the total shares.
The Vanguard Group, Inc. holds 9.78M shares, accounting for 11.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.39M shares, accounting for 5.30% of the total shares.
State Street Investment Management (US) holds 3.83M shares, accounting for 4.62% of the total shares.
Victory Capital Management Inc. holds 2.64M shares, accounting for 3.18% of the total shares.
Geode Capital Management, L.L.C. holds 2.12M shares, accounting for 2.56% of the total shares.
What are the top three shareholder types of Labcorp Holdings Inc?
The top three shareholder types of Labcorp Holdings Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Labcorp Holdings Inc (LH)?
As of 2025Q4, 1803 institutions hold shares of Labcorp Holdings Inc, with a combined market value of approximately 80.86M, accounting for 97.54% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.70%.
What is the biggest source of revenue for Labcorp Holdings Inc?
In FY2021, the -- business generated the highest revenue for Labcorp Holdings Inc, amounting to -- and accounting for --% of total revenue.
